PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.01
D/E less than half of AXSM's 0.68. Charlie Munger would verify if this conservative approach provides competitive advantages.
16.45
Dangerously higher net debt above 1.5x AXSM's 2.98. Jim Chanos would check for potential debt spiral risks.
No Data
No Data available this quarter, please select a different quarter.
21.47
Current ratio exceeding 1.5x AXSM's 6.20. Charlie Munger would verify if this advantage translates to better supplier terms.
No Data
No Data available this quarter, please select a different quarter.